TrialAmerican journal of hematology2026

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.

Julio C Chavez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.